Vertex Pharmaceuticals and RNA therapeutics developer Ribometrix, headquartered in Durham, North Carolina, have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix’s proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional (3D) RNA […]

Cambridge-based, clinical-stage biotech Moderna has announced a multi-year research collaboration with Harvard University to identify and develop novel therapeutic approaches that could improve the lives of patients with immunological diseases. Additional funding from Moderna to Harvard Medical School (HMS) will establish an initiative at HMS called the Alliance for RNA Therapies for the Modulation of […]

Boston-based Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, has announced that its board of directors has appointed Damien McDevitt, Ph.D., a member of its board of directors, as interim chief executive officer, effective immediately. In addition, Michael J. Yang and Joseph ‘Skip’ Klein III have joined the Company’s board of directors. The company also […]

Bayer and Partners HealthCare’s founding members Brigham and Women’s Hospital (BWH) and Massachusetts General Hospital (MGH) have announced the launch of a joint lab to research new drug candidates to treat chronic lung diseases. The joint lab will host scientists from all three parties and Bayer is investing more than $30 million to fund joint […]